The global anticoagulant reversal drugs market was valued at USD 1.38 billion in 2024 and is anticipated to reach USD 2.78 billion by 2030, growing at a compound annual growth rate (CAGR) of 12.3% from 2025 to 2030. This growth is primarily driven by the increasing incidence of thromboembolic disorders. Additionally, an aging population contributes to a higher prevalence of conditions that require anticoagulation therapy, further driving demand.